Stem cell research forges ahead

Written by: Cynthia Hernandez on October 7, 2010.

Despite opposition, use of embryos for testing continues

Why is the United States such a powerful country? Is it because we have a democracy?

Is it because our military capabilities exceed those of others? Is it because we have succeeded at prioritizing those policies that are most beneficial to the citizenry?

From civil rights movements to fighting a war on terror, the United States is at the forefront of advancement or is it?

It is safe to assume that most Americans support research and education. It is usually the case that anyone who is influential in some form or another has a significant educational background.

From lobbyists to police officers to the president of the United States, education plays a critical role in numerous professions.

One critical aspect of education is research. For example, political scientists research the political implications of differing democratic systems, biologists research DNA and English scholars research literary and poetic forms.

These topics will usually only interest and be of importance to people in similar fields.

But when research on a particular topic ignites controversy, it becomes a battle of academia versus personal beliefs.

Read the original here:
Stem cell research forges ahead

Salk, Stanford partner in genomics program

Instead of being shut out of a $40 million stem cell grant awarded to Stanford University, San Diego researchers will be major partners, say the scientists who lead the project.

Joseph Ecker of the Salk Institute and Michael Snyder of Stanford say that under an informal arrangement, they will jointly allocate money granted from the California Institute for Regenerative Medicine for a new center on stem cell genomics. CIRM is responsible for distributing $3 billion in state bond money to turn stem cell research into disease treatments.

Joseph Ecker, a Salk Institute researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Salk Institute

Genomics, the study of the complete set of genes and DNA in an organism, is necessary to help understand how stem cells function. Stem cells contain virtually the same genes as adult cells but differ in which genes are turned on and off. The signals that cause stem cells to differentiate are not well understood.

By analyzing the genomes of stem cells, researchers expect to better understand how stem cells can produce more stem cells, and which genes are involved in directing stem cells down the path to becoming adult cells of interest, such as islet cells that make insulin, bone or retinal cells.

Last months decision had been characterized as a big win for Stanford, because the university had been awarded the grant over competing applications, including one from The Scripps Research Institute and San Diego DNA sequencing giant Illumina.

Ecker and Snyder said that belief is a misunderstanding, because their proposal is a cooperative venture involving extensive participation from San Diego biomedical scientists.

Michael Snyder, a Stanford University researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Stanford University

The leadership issue is confusing, because CIRM requires a single institute to be listed as the lead on funding proposals, even if the institutions are sharing leadership, Ecker said by email. In fact, Mike Snyder and I, by proxy Stanford and Salk, are equal partners. Responsibility for administration of the center will fall equally to Stanford and Salk researchers, as well as strategic steering and decision-making on what projects to pursue.

Besides Salk and Stanford, partners are UC San Diego, the Ludwig Institute for Cancer Research, the J. Craig Venter Institute, The Scripps Research Institute and UC Santa Cruz. The Howard Hughes Medical Institute also plays a role.

See more here:
Salk, Stanford partner in genomics program

Stem Cell Therapy | Advanced Orthopedics | Regenerative …

It's been nothing but 100% improvement.It just continues to get better.Ive been avoiding doing stairways and I have to be real careful climbing in and out of equipment. I find myself being a lot more relaxed, not having the problems, not having the pain. I don't have the swelling in my knees that I used to have and it hasnt been waking me up at night. View my video testimonial here My name is Susan and Im 62 year old I just finished having my second PRP treatment and Im very, very happy with the results I can do all kinds of things I wasn't able to do beforeI believe my knee will continue to get better as the cartilage grows. Thank you! View my video testimonial here

Many thanks to the Stem MD team for giving me the use of my hands back, pain free! Professional, courteous and compassionate, describes this team of caring people. To anyone considering this procedure, I say you will be amazed and thankful at the results.

Lenita Brewer Ansonia, Ohio

Thank you for giving my life and health back. The PRP treatment worked wonders and helped alleviate the pain. I highly recommend the anti-inflammatory diet, Dr. Purita suggested. My body noticed the difference and I lost 35 pounds. I can finally be active again!

Jennica Califf Coconut Creek, Florida

I thought there was no hope for my chronic back pain. I am so thankful I found out about Dr. Purita and stem cells. I have had back pain for over 5 years, debilitating me to do everyday things. Today my pain has gone down 50%. I tell all my friends and family and wish everyone knew about this wonderful treatment. Thank you so much Dr. Purita

It has been 3 months since my mothers procedure to her knees. Now, my mom climbs into the van without any help, before we had to pull her up and assist her. She does not take painkillers anymore, even her recurring bladder infection and Diabetes is well controlled. All my friends and colleagues are super amazed every time I show them a video of my mom dancing. Thank you so much what you have done for my mom it is truly wonderful and I am forever indebted to you.

Malou Aragon-De Veyra Philippines

I came to Dr. Purita on the advice of a friend when I expressed trepidations about cortisone shots or the possibility no matter how remote of a joint replacement. I was a wrestler in high school and college, and this had done no good for my kneed as I aged. I had no expectations, only hope that somehow my knees could be made less fragile by the stem cell therapy my friend described. I had gotten to the point where any down stairs journey or stepping down off a van or public bus was excruciating, to the point that I usually made an exclamation that wasn't fit for public utterance every time I stepped off a bus or a van. My expectations were neutral at best. I had no idea as to how this stem cell therapy would impact my general health whatsoever. I can say without hesitation that the results have been beyond what I could have hoped. My knees are now cooperative to the point that sometimes I take the stairs down just because I can. I have resumed walking the stairs up and down at work, and I can say that I really don't think about anything I want to do where my kneed are involved. I am not quite where I was when I was 20, but 35 is a real thought, my flexibility and agility are restored to a level I could not have imagined. As an additional part of the procedure Dr. Purita also injected stem cell into my left hand, which has been diagnosed with some arthritis. The results are less instantaneously spectacular, but the had continues to improve. I no longer sit in my office while my hand burns with joint pain, my movement and most of my strength are improving daily, and I have a feeling that within a month or so I will have the same level of improvement I have experiences with my knees. Many thanks to the friend who recommended the trip to Dr. Purita's office, and to Dr. Purita and his staff who have put thoughts of joint replacement and the mad merry-go-round of cortisone shots far in the past for me.

Mark Burns Hypoluxo, Florida

See the rest here:
Stem Cell Therapy | Advanced Orthopedics | Regenerative ...

Researchers turn adult cells back into stem cells | wfaa …

by KAREN WEINTRAUB

USA TODAY Special Contributor

Posted on January 29, 2014 at 10:32 AM

In a step that has implications for stem cell research, human biology and the treatment of disease, researchers in Japan and at Harvard University have managed to turn adult cells back into flexible stem cells without changing their DNA.

The researchers discovered that they could put cells in various challenging circumstances including in acidic solutions and under physical pressure and turn mature blood cells into cells that were capable of turning into virtually any cell in the body.

The research, published today in the journal Nature, was in mice. If it can be repeated in people, it has the potential to transform research using stem cells to treat disease, and it may lead to a new understanding of how the body heals from injury, said Charles Vacanti, the Harvard Medical School stem cell and tissue engineering biologist who led the research.

Biology textbooks say that once a cell matures to serve a specific role, like, say a red blood cell, it can never go back into a less mature state. Vacanti and his colleagues say their new research upends that dogma.

"This study demonstrates that any mature cell when placed in the right environment can go back, become a stem cell, which then has the potential to become any cell needed by that tissue," said Vacanti, also of Brigham and Women's Hospital in Boston.

He believes that that process happens naturally in the body after injury, and the more significant the injury, the farther back these cells will revert. "With a very significant injury, you will cause it to revert clear back to what is basically an embryonic stem cell," he said.

In an early embryo, all cells are stem cells, capable of turning into any cell in the body. As the fetus develops, those cells differentiate into cells with specific functions in muscles, blood, organs, etc. Some of those mature cells develop diseases and injuries. The promise of stem cells as yet largely unrealized is to provide patients with healthy versions of their own cells that can then repair damage and reverse disease.

Originally posted here:
Researchers turn adult cells back into stem cells | wfaa ...

Cell Therapy Cancer

Other common name(s): cellular therapy, fresh cell therapy, live cell therapy, glandular therapy, xenotransplant therapy

Scientific/medical name(s): none

In cell therapy, processed tissue from the organs, embryos, or fetuses of animals such as sheep or cows is injected into patients. Cell therapy is promoted as an alternative form of cancer treatment.

Available scientific evidence does not support claims that cell therapy is effective in treating cancer or any other disease. Serious side effects can result from cell therapy. It may in fact be lethalseveral deaths have been reported. It is important to distinguish between this alternative method involving animal cells and mainstream cancer treatments that use human cells, such as bone marrow transplantation.

In cell therapy, live or freeze-dried cells or pieces of cells from the healthy organs, fetuses, or embryos of animals such as sheep or cows are injected into patients. This is supposed to repair cellular damage and heal sick or failing organs. Cell therapy is promoted as an alternative therapy for cancer, arthritis, heart disease, Down syndrome, and Parkinson disease.

Cell therapy is also marketed to counter the effects of aging, reverse degenerative diseases, improve general health, increase vitality and stamina, and enhance sexual function. Some practitioners have proposed using cell therapy to treat AIDS patients.

The theory behind cell therapy is that the healthy animal cells injected into the body can find their way to weak or damaged organs of the same type and stimulate the body's own healing process. The choice of the type of cells to use depends on which organ is having the problem. For instance, a patient with a diseased liver may receive injections of animal liver cells. Most cell therapists today use cells taken from taken from the tissue of animal embryos.

Supporters assert that after the cells are injected into the body, they are transported directly to where they are most needed. They claim that embryonic and fetal animal tissue contains therapeutic agents that can repair damage and stimulate the immune system, thereby helping cells in the body heal.

The alternative treatment cell therapy is very different from some forms of proven therapy that use live human cells. Bone marrow transplants infuse blood stem cellsfrom the patient or a carefully matched donorafter the patients own bone marrow cells have been destroyed. Studies have shown that bone marrow transplants are effective in helping to treat several types of cancer. In another accepted procedure, damaged knee cartilage can be repaired by taking cartilage cells from the patient's knee, carefully growing them in the laboratory, and then injecting them back into the joint. Approaches involving transplants of other types of human stem cells are being studied as a possible way to replace damaged nerve or heart muscle cells, but these approaches are still experimental.

First, healthy live cells are harvested from the organs of juvenile or adult live animals, animal embryos, or animal fetuses. These cells may be taken from the brain, pituitary gland, thyroid gland, thymus gland, liver, kidney, pancreas, spleen, heart, ovaries, testicles, or even from whole embryos. Patients might receive one or several types of animal cells. Some cell therapists inject fresh cells into their patients. Others freeze them first, which kills the cells, and they may filter out some of the cell components. Frozen cell extracts have a longer "shelf life" and can be screened for disease. Fresh cells cannot be screened. A course of cell therapy to address a specific disease might require several injections over a short period of time, whereas cell therapy designed to treat the effects of aging and "increase vitality" may involve injections received over many months.

Excerpt from:
Cell Therapy Cancer

Over 5,000 Cubans receive stem cell treatment: Expert

Havana, Feb 16 (IANS): More than 5,000 patients have received stem cell treatment in Cuba since its procedure was introduced in 2004, a medical expert said.

Porfirio Hernandez, researcher and vice director at the Hematology and Immunology Institute in Cuba, said the stem cell treatment method has been implemented in 13 of the 15 provinces in Cuba.

As a widely acknowledged pioneer of this practice, Hernandez said that more than 60 percent of patients receiving the treatment had suffered from severe ischemia at lower limbs and other blood vessel related ailments, reported Xinhua.

The therapy has also been used to reduce the sufferings of patients with severe orthopedic and cardiac problems, Hernandez added.

Stem cells are capable of self-renewing, regenerating tissues damaged by diverse disease, traumas, and ageing, and stimulating the creation of new blood vessels.

Please note that under 66A of the IT Act, sending offensive or menacing messages through electronic communication service and sending false messages to cheat, mislead or deceive people or to cause annoyance to them is punishable. It is obligatory on Daijiworld to provide the IP address and other details of senders of such comments, to the authority concerned upon request.

Hence, sending offensive comments using daijiworld will be purely at your own risk, and in no way will Daijiworld.com be held responsible.

Continued here:
Over 5,000 Cubans receive stem cell treatment: Expert

After beating cancer, Ottawa hockey player Chris Kushneriuk looks to resume his career

The last time we spoke with Chris Kushneriuk he was at the Indiana University Cancer Center awaiting stem cell treatments and chemotherapy.

It was early December, 2012, and Kushneriuk, a pro hockey player from Gloucester, had just been told by Canadian doctors he had about six months to live. Some Christmas present.

Kushneriuks supreme hockey conditioning, though it would ultimately prove a weapon, was no defence against the initial cancer, his body ravaged by what began as testicular cancer but which had spread to his liver, kidney and lymph nodes. Your basic nightmare scenario.

As he spoke by phone from Indianapolis, in the care of Lance Armstrongs cancer doctor, Lawrence Einhorn, Chris was a few weeks away from his 26th birthday, still talking positively, convinced this was a battle he could win.

Happily, 14 months later we can report that Kushneriuk is not only alive and well, hes been cleared to play hockey again and is looking to sign with an ECHL team in the near future. If we were to take out a classified ad on Chris behalf, it might read like this: Wanted, a roster spot for a player of unparalleled heart and will. Team-first type, leader, survivor. Ready to report immediately.

Small wonder that when Kushneriuk resumes his hockey career, he has a gift in mind for Dr. Einhorn.

Im definitely going to give him my next jersey, for whichever team I play, Kushneriuk says. He saved my life, he deserves a jersey.

And then Chris laughs at the tradeoff. A jersey for a life.

The journey Kushneriuk took to arrive at this point is a story of personal triumph and modern medicine, but also a tale of friendship and community hockey support that made it possible for Chris to afford the type of bold surgical treatment that defied the initial doomsday prognosis.

Read more:
After beating cancer, Ottawa hockey player Chris Kushneriuk looks to resume his career

Chef Kerry Simon undergoes stem-cell transplants at Mayo Clinic in Minnesota

Erik Kabik/Retna/ErikKabik.com

Kerry Simon and Barry Dakake at Chefs to the Max, a fundraising dinner for food critic Max Jacobson, at Rx Boiler Room on Sunday, Jan. 19, 2014, in MandalayPlace.

By Robin Leach (contact)

Thursday, Feb. 13, 2014 | 2:08 p.m.

Celebrity Iron Chef champion Kerry Simon underwent the first of two days of initial stem-cell transplants at the Mayo Clinic in Minnesota on Wednesday. After todays second set of spinal injections, Kerry will return to Las Vegas on Friday.

Before he returns to Rochester in early March for more intensive sessions of stem-cell transplants, he will preside over his Feb. 27 celebrity chef and rocker showcase at the Keep Memory Alive event center in the Cleveland Clinic Lou Ruvo Center for Brain Health downtown.

Word from Kerry, a 2013 Silver State Award recipient, on Wednesday night was that he was in good spirits, although very tired, resting comfortably and optimistic with the medical procedure. There is no known cure or treatment for Multiple Systems Atrophy (a stronger, more-aggressive form of Parkinsons) hes fighting that we reported in December.

On Friday, he meets here with 20 volunteers who formed a committee to organize the Feb. 27 events. His good pal comedy actor Bill Murray will serve as MC, and Christian Kohlberg will join him as auctioneer.

Before he underwent surgery, Kerry told me this week: I cannot believe the support we are getting for our Fight MSA campaign. It is unbelievable. I am deeply touched by all these wonderful people helping out at the drop of a hat with nothing more in mind than to conquer this terrible disease.

Im not going to let it stop me doing what I must do.

Visit link:
Chef Kerry Simon undergoes stem-cell transplants at Mayo Clinic in Minnesota

Harvard scientists find cell fate switch that decides liver, or pancreas?

PUBLIC RELEASE DATE:

13-Feb-2014

Contact: Joseph Caputo joseph_caputo@harvard.edu 617-496-1491 Harvard University

Harvard stem cell scientists have a new theory for how stem cells decide whether to become liver or pancreatic cells during development. A cell's fate, the researchers found, is determined by the nearby presence of prostaglandin E2, a messenger molecule best known for its role in inflammation and pain. The discovery, published in the journal Developmental Cell, could potentially make liver and pancreas cells easier to generate both in the lab and for future cell therapies.

Wolfram Goessling, MD, PhD, and Trista North, PhD, both principal faculty members of the Harvard Stem Cell Institute (HSCI), identified a gradient of prostaglandin E2 in the region of zebrafish embryos where stem cells differentiate into the internal organs. Experiments conducted by postdoctoral fellow Sahar Nissim, MD, PhD, in the Goessling lab showed how liver-or-pancreas-fated stem cells have specific receptors on their membranes to detect the amount of prostaglandin E2 hormone present and coerce the cell into differentiating into a specific organ type.

"Cells that see more prostaglandin become liver and the cells that see less prostaglandin become pancreas," said Goessling, a Harvard Medical School Assistant Professor of Medicine at Brigham and Women's Hospital and Dana-Farber Cancer Institute. "This is the first time that prostaglandin is being reported as a factor that can lead this fate switch and essentially instruct what kind of identity a cell is going to be."

The researchers next collaborated with the laboratory of HSCI Affiliated Faculty member Richard Maas, MD, PhD, Director of the Genetics Division at Brigham and Women's Hospital, to see whether prostaglandin E2 has a similar function in mammals. Richard Sherwood, PhD, a former graduate student of HSCI Co-director Doug Melton, was successfully able to instruct mouse stem cells to become either liver or pancreas cells by exposing them to different amounts of the hormone. Other experiments showed that prostaglandin E2 could also enhance liver growth and regeneration of liver cells.

Goessling and his research partner North, a Harvard Medical School Assistant Professor of Pathology at Beth Israel Deaconess Hospital, first became intrigued by prostaglandin E2 in 2005, as postdoctoral fellows in the lab of HSCI Executive Committee Chair Leonard Zon, MD. It caught their attention during a chemical screen exposing 2,500 known drugs to zebrafish embryos to find any that could amplify blood stem cell populations. Prostaglandin E2 was the most successful hit the first molecule discovered in any system to have such an effectand recently successfully completed Phase 1b clinical trials as a therapeutic to improve cord blood transplants.

"Prostaglandin might be a master regulator of cell growth in different organs," Goessling said. "It's used in cord blood, as we have shown, it works in the liver, and who knows what other organs might be affected by it."

With evidence of how prostaglandin E2 works in the liver, the researchers next want to calibrate how it can be used in the laboratory to instruct induced pluripotent stem cellsmature cells that have been reprogrammed into a stem-like stateto become liver or pancreas cells. The scientists predict that such a protocol could benefit patients who need liver cells for transplantation or who have had organ injury.

More:
Harvard scientists find cell fate switch that decides liver, or pancreas?

Salk, Stanford equal partners in stem cell genomics program

Instead of being shut out of a $40 million stem cell grant awarded to Stanford University, San Diego researchers will be major partners, say the scientists who lead the project.

Joseph Ecker of the Salk Institute and Michael Snyder of Stanford say that under an informal arrangement, they will jointly allocate money granted from the California Institute for Regenerative Medicine for a new center on stem cell genomics. CIRM is responsible for distributing $3 billion in state bond money to turn stem cell research into disease treatments.

Joseph Ecker, a Salk Institute researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Salk Institute

Genomics, the study of the complete set of genes and DNA in an organism, is necessary to help understand how stem cells function. Stem cells contain virtually the same genes as adult cells but differ in which genes are turned on and off. The signals that cause stem cells to differentiate are not well understood.

By analyzing the genomes of stem cells, researchers expect to better understand how stem cells can produce more stem cells, and which genes are involved in directing stem cells down the path to becoming adult cells of interest, such as islet cells that make insulin, bone or retinal cells.

Last months decision had been characterized as a big win for Stanford, because the university had been awarded the grant over competing applications, including one from The Scripps Research Institute and San Diego DNA sequencing giant Illumina.

Ecker and Snyder said that belief is a misunderstanding, because their proposal is a cooperative venture involving extensive participation from San Diego biomedical scientists.

Michael Snyder, a Stanford University researcher and co-principal investigator of the new center for stem cell genomics created with a $40 million grant from the California Institute for Regenerative Medicine. / Stanford University

The leadership issue is confusing, because CIRM requires a single institute to be listed as the lead on funding proposals, even if the institutions are sharing leadership, Ecker said by email. In fact, Mike Snyder and I, by proxy Stanford and Salk, are equal partners. Responsibility for administration of the center will fall equally to Stanford and Salk researchers, as well as strategic steering and decision-making on what projects to pursue.

Besides Salk and Stanford, partners are UC San Diego, the Ludwig Institute for Cancer Research, the J. Craig Venter Institute, The Scripps Research Institute and UC Santa Cruz. The Howard Hughes Medical Institute also plays a role.

View post:
Salk, Stanford equal partners in stem cell genomics program